Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International Observational Prospective Study On Long-Term Response To Botulinum Toxin Type A (BoNT-A) Injections In Subjects Suffering From Idiopathic Cervical Dystonia (CD) - Pharmaco-Economic Impact

Trial Profile

An International Observational Prospective Study On Long-Term Response To Botulinum Toxin Type A (BoNT-A) Injections In Subjects Suffering From Idiopathic Cervical Dystonia (CD) - Pharmaco-Economic Impact

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jan 2019

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Torticollis
  • Focus Therapeutic Use
  • Acronyms INTEREST IN CD2
  • Sponsors Ipsen
  • Most Recent Events

    • 09 Oct 2018 Results from INTEREST IN CD1 [NCT00833196] INTER- EST IN CD2 [NCT01753349] and ANCHOR-CD [NCT01314365] describing the use of injection guidance (at baseline/ first injection visit and at 1 year) in 585 subjects, presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders.
    • 09 Oct 2018 Results from INTEREST IN CD1 [NCT00833196] INTER- EST IN CD2 [NCT01753349] and ANCHOR-CD [NCT01314365] describing the patterns of Cervical dystonia and injection parameters in subjects routinely treated with aboBoNT-A over 1 year (N=585), presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders.
    • 09 Oct 2018 Results presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top